Ensign Peak Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ensign Peak Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-66,655	Closed	-$2.83M	–	1762
2023 Q4	$2.83M	Buy	66,655 +37,365	+128%	+$1.07M	0.01%	783
2023 Q3	$639K	Hold	29,290	–	–	﹤0.01%	1497
2023 Q2	$931K	Hold	29,290	–	–	﹤0.01%	1320
2023 Q1	$714K	Hold	29,290	–	–	﹤0.01%	1498
2022 Q4	$924K	Buy	29,290 +12,100	+70%	+$341K	﹤0.01%	1223
2022 Q3	$486K	Buy	17,190 +5,540	+48%	+$165K	﹤0.01%	1472
2022 Q2	$308K	Sell	11,650 -71,159	-86%	-$2.02M	﹤0.01%	1670
2022 Q1	$2.9M	Hold	82,809	–	–	0.01%	737
2021 Q4	$2.69M	Buy	82,809 +11,650	+16%	+$411K	0.01%	861
2021 Q3	$2.1M	Hold	71,159	–	–	﹤0.01%	1098
2021 Q2	$1.82M	Hold	71,159	–	–	﹤0.01%	1177
2021 Q1	$977K	Buy	+71,159	New	+$1.04M	﹤0.01%	1434

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ensign Peak Advisors's CERE Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 66,655 shares — an estimated $2.83M sold.

Ensign Peak Advisors first reported a position in CERE in Q1 2021 and held it in 12 quarters. The position peaked at $2.9M in Q1 2022. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

Ensign Peak Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Ensign Peak Advisors sold 66,655 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $2.83M.
Ensign Peak Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
Ensign Peak Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.9M in Q1 2022.
210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.